Related Experiment Video
Updated: Jul 14, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Surgical resection in metastatic gastrointestinal stromal tumors
1Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors of the gastrointestinal tract. Traditionally, surgery has been the primary treatment modality for these tumors, with only modest results. The recent development of kinase inhibitors (most notably, imatinib mesylate) has provided a new paradigm for the treatment of this disease. Response rates approaching 60% have been seen in studies in patients with advanced disease. Previously, chemotherapy played little role in the treatment of this disease. Now, however, treatment with kinase inhibitors can increase the number of patients who may potentially benefit from surgical intervention. Many questions regarding the use of kinase inhibitors remain. Most importantly, the optimal duration of treatment before surgical intervention and following both complete and incomplete tumor resection remains to be elucidated. Ongoing prospective trials have the potential to provide some of these answers in the near future.
Insights
Gastrointestinal stromal tumors (GISTs) are rare. Kinase inhibitors like imatinib mesylate offer new treatment options, improving outcomes and potentially enabling surgery for advanced GIST cases. Further research is ongoing.
Area of Science:
- Oncology
- Gastrointestinal Surgery
- Medical Therapeutics
Background:
- Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms.
- Surgery was the traditional primary treatment for GISTs, yielding limited success.
- Chemotherapy had a minimal role in GIST management historically.
Purpose of the Study:
- To review the evolving treatment landscape for GISTs.
- To highlight the impact of kinase inhibitors on GIST management.
- To identify key unanswered questions regarding kinase inhibitor therapy in GISTs.
Main Methods:
- Review of current literature on GIST treatment.
- Analysis of the role of kinase inhibitors in advanced GIST.
- Discussion of neoadjuvant and adjuvant therapy concepts.
Main Results:
- Kinase inhibitors, such as imatinib mesylate, have revolutionized GIST treatment.
- Response rates of up to 60% are observed in advanced GIST patients treated with kinase inhibitors.
- Kinase inhibitors can downstage tumors, making more patients eligible for surgical resection.
Conclusions:
- Kinase inhibitors represent a significant advancement in GIST therapy.
- Optimal duration of kinase inhibitor treatment before and after surgery requires further investigation.
- Ongoing clinical trials aim to address remaining questions regarding neoadjuvant and adjuvant kinase inhibitor therapy for GISTs.
